JP2009501801A - イブプロフェンとファモチジンとを含有する医薬およびその投与 - Google Patents

イブプロフェンとファモチジンとを含有する医薬およびその投与 Download PDF

Info

Publication number
JP2009501801A
JP2009501801A JP2008522937A JP2008522937A JP2009501801A JP 2009501801 A JP2009501801 A JP 2009501801A JP 2008522937 A JP2008522937 A JP 2008522937A JP 2008522937 A JP2008522937 A JP 2008522937A JP 2009501801 A JP2009501801 A JP 2009501801A
Authority
JP
Japan
Prior art keywords
famotidine
ibuprofen
dosage form
oral dosage
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501801A5 (OSRAM
Inventor
ジョージ ティドマーシュ，
バリー エル． ゴロムビク，
テンシュアン リー，
Original Assignee
ホライゾン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ホライゾン セラピューティクス， インコーポレイテッド filed Critical ホライゾン セラピューティクス， インコーポレイテッド
Publication of JP2009501801A publication Critical patent/JP2009501801A/ja
Publication of JP2009501801A5 publication Critical patent/JP2009501801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008522937A 2005-07-18 2006-07-18 イブプロフェンとファモチジンとを含有する医薬およびその投与 Pending JP2009501801A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70048105P 2005-07-18 2005-07-18
PCT/US2006/028075 WO2007012019A2 (en) 2005-07-18 2006-07-18 Medicaments containing famotidine and ibuprofen and administration of same

Publications (2)

Publication Number Publication Date
JP2009501801A true JP2009501801A (ja) 2009-01-22
JP2009501801A5 JP2009501801A5 (OSRAM) 2009-08-27

Family

ID=37669550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522937A Pending JP2009501801A (ja) 2005-07-18 2006-07-18 イブプロフェンとファモチジンとを含有する医薬およびその投与

Country Status (8)

Country Link
US (3) US20070043096A1 (OSRAM)
EP (1) EP1919288A4 (OSRAM)
JP (1) JP2009501801A (OSRAM)
CN (1) CN101257800B (OSRAM)
CA (1) CA2615496C (OSRAM)
IL (1) IL188732A (OSRAM)
NZ (1) NZ565846A (OSRAM)
WO (2) WO2007012019A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534189A (ja) * 2018-08-17 2021-12-09 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3516632B2 (ja) 2000-04-27 2004-04-05 オリジン電気株式会社 光ディスク基板の貼り合わせ方法及び装置
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
BRPI0714937A2 (pt) * 2006-07-18 2013-03-26 Horizon Therapeutics Inc forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria
US20150224056A1 (en) * 2006-07-18 2015-08-13 Horizon Pharma Usa, Inc. Pharmaceutical compositions of ibuprofen and famotidine
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
NZ587202A (en) * 2008-01-04 2013-03-28 Schabar Res Associates Llc Methods for measuring a patient response upon administration of a drug and compositions thereof
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
MX337488B (es) 2008-07-21 2016-03-08 Si Group Inc Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes.
US20120003304A1 (en) * 2010-07-02 2012-01-05 Fmc Corporation Solid Forms
WO2013054352A1 (en) * 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
CN102247371A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布洛芬和拉呋替丁为活性成分的药物组合物
CN103083314A (zh) * 2011-10-28 2013-05-08 四川大学 具有胃肠道保护作用的复方布洛芬
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
MA43114A (fr) * 2015-10-30 2018-09-05 Cancer Prevention Pharmaceuticals Inc Formulation combinée à dose fixe d'éflornithine et sulindac
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
CA3214612A1 (en) * 2021-03-24 2022-09-29 Johnson & Johnson Consumer Inc. A pharmaceutical composition comprising famotidine
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06239738A (ja) * 1992-12-01 1994-08-30 Spirig Ag Pharmazeut Praeparate Ｓ（＋）イブプロフェンを含有する薬剤
JPH08502254A (ja) * 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
JPH11502209A (ja) * 1995-03-21 1999-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 非ステロイド性鎮痛薬の急速放出性透明製剤
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
SK279279B6 (sk) * 1991-05-13 1998-09-09 The Boots Company Plc S(-)-nátrium-2-(4-izobutylfenyl)propionát-dihydrát
ES2130152T3 (es) * 1991-12-06 1999-07-01 Glaxo Group Ltd Medicamentos para tratar dolencias inflamatorias o para analgesia que contienen un nsaid y ranitidina/citrato de bismuto.
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ATE222502T1 (de) * 1996-07-30 2002-09-15 Novartis Ag Kombinationspräparat mit hemmender wirkung auf die abstossung von transplantaten, autoimmunerkrankungen und entzündungen, welches cyclosporin a und 40-0-(2-hydroxyethyl)-rapamycin enthält
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
WO2000028988A1 (en) * 1998-11-17 2000-05-25 Nitromed, Inc. Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
KR20020062323A (ko) * 1999-12-06 2002-07-25 펜웨스트 파머슈티칼즈 컴파니 제약학적 초붕해제
ES2348710T5 (es) * 2001-06-01 2014-02-17 Pozen, Inc. Composiciones farmacéuticas para el suministro coordinado de NSAID
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
WO2004103955A1 (en) * 2003-03-05 2004-12-02 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
CA2511158A1 (en) * 2005-06-29 2006-12-29 Medical Futures Inc. Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08502254A (ja) * 1992-09-29 1996-03-12 メルク エンド カンパニー インコーポレーテッド イブプロフェン−ｈ▲下２▼拮抗薬配合物
JPH06239738A (ja) * 1992-12-01 1994-08-30 Spirig Ag Pharmazeut Praeparate Ｓ（＋）イブプロフェンを含有する薬剤
JPH11502209A (ja) * 1995-03-21 1999-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 非ステロイド性鎮痛薬の急速放出性透明製剤
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012016662; 日本病院薬剤師会雑誌 ３９（２）, 2003, ２０１-２０４ *
JPN6012016664; Ｎｅｗ　Ｅｎｇｌａｎｄ　Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎｅ ３３４（２２）, 1996, １４３５-１４３９ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534189A (ja) * 2018-08-17 2021-12-09 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤
JP7469293B2 (ja) 2018-08-17 2024-04-16 エイドス セラピューティクス，インコーポレイティド Ａｇ１０の製剤

Also Published As

Publication number Publication date
CA2615496C (en) 2014-11-18
WO2007012019A2 (en) 2007-01-25
WO2007012022A3 (en) 2007-07-19
IL188732A0 (en) 2008-08-07
US20070043097A1 (en) 2007-02-22
IL188732A (en) 2014-07-31
US20070043096A1 (en) 2007-02-22
AU2006269894A1 (en) 2007-01-25
CA2615496A1 (en) 2007-01-25
CN101257800B (zh) 2012-07-18
WO2007012022A2 (en) 2007-01-25
WO2007012019A3 (en) 2007-11-01
CN101257800A (zh) 2008-09-03
US20140066485A1 (en) 2014-03-06
EP1919288A4 (en) 2009-12-16
NZ565846A (en) 2011-12-22
EP1919288A2 (en) 2008-05-14

Similar Documents

Publication Publication Date Title
US20140066485A1 (en) Medicaments containing famotidine and ibuprofen and administration of same
US8067451B2 (en) Methods and medicaments for administration of ibuprofen
US8067033B2 (en) Stable compositions of famotidine and ibuprofen
EP2043637B8 (en) Methods and medicaments for administration of ibuprofen
BRPI0708059A2 (pt) formulação de niacina de baixo rubor
CN101516368B (zh) 用于施用布洛芬的方法和药物
AU2006269894B2 (en) Medicaments containing famotidine and ibuprofen and administration of same
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
HK1169038A (en) Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120329

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20120425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130304